Leukosight, Inc. is a biopharmaceutical company focused on developing innovative anti-inflammatory therapeutics aimed at treating autoimmune and inflammatory diseases. Their primary technology involves proprietary recombinant polypeptides designed to "reprogram" white blood cells (leukocytes) to produce immunoregulatory molecules instead of inflammatory cytokines. This approach is intended to create therapeutics that are potentially less toxic and more effective than existing treatments, which typically inhibit inflammatory mediators. The company is currently conducting pre-clinical trials on its first anti-inflammatory compound, known as "Fc-Dimers," which has shown promise in reversing paralysis in animal models of multiple sclerosis and preventing platelet depletion in conditions like idiopathic thrombocytopenic purpura (ITP).

Leukosight's strategy leverages the body's natural mechanisms by inducing the production of its own immunosuppressants, thereby minimizing the risk of immunogenic reactions associated with some human recombinant proteins. The company aims to address the growing demand for effective treatments in the field of autoimmune diseases, particularly as existing therapies like intravenous immunoglobulin (IVIG) face supply challenges. By focusing on conditions such as multiple sclerosis, Leukosight seeks to provide patients with safer and more effective therapeutic options, ultimately enabling them to lead healthier lives.

United States

Leukosight is an online pharmacy that offers remedies of the highest quality, low prices, and a fast delivery system.

Leukosight

Company Details